课题基金 / 基金详情

INHIBITION OF THE HIV-1 REV TRANSACTIVATOR

INHIBITION OF THE HIV-1 REV TRANSACTIVATOR
HIV-1 REV 反式激活因子的抑制
批准号:
3489809
负责人:
Anilkumar Dhundale
金额:
$4.98万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-08-15 至 1994-02-15

项目摘要

项目成果

Anilkumar Dhundale的其他基金

相似基金

相关文献

中文摘要
翻译
获得性免疫缺陷综合症(艾滋病),一种影响数百万人的疾病, 在全球范围内,患者死亡率很高。的 这种疾病的病原体,传染性逆转录病毒HIV-1, 被证明对治疗干预是难治的。唯一使用的药物 今天的临床目标是病毒逆转录酶。这些药物充其量 暂时延缓疾病进展。此外,这些代理商还表现出 在有效治疗剂量下具有显著毒性。目前,其他 靶向逆转录酶、病毒蛋白酶或病毒蛋白酶的化合物 达特反式激活因子也在临床试验中。但似乎 很明显,可能需要额外的药物来靶向其他步骤, 病毒复制一个这样的靶点是Rev反式激活因子, 对病毒复制至关重要。Rev的功能是诱导核 导出部分拼接和未拼接的病毒信息, 感染性HIV-1的结构基因产物和RNA基因组 粒子我们建议建立一个Rev依赖性的双报告基因测定法, 结合Oncogene Science独特的基于细胞的高通量 筛选技术,能够评估超过123,000 化合物,以确定铅化合物从NCI的自然 产品储存库,它特异性抑制HIV-1 Rev反式- 活化剂。
英文摘要
Acquired Immunodeficiency Syndrome (AIDS), a disease affecting millions of individuals worldwide, has a high incidence of patient mortality. The etiological agent of this disease, the infectious retrovirus HIV-l, has proven refractory to therapeutic intervention. The only drugs used in the clinic today target the viral reverse transcriptase. At best such drugs temporarily delay disease progression. In addition, these agents exhibit significant toxicity at the effective therapeutic dose. Presently, other compounds, targeting reverse transcriptase, viral protease, or the viral Tat trans-activator, ale also in clinical trials. However, it appears clear that additional drugs may be needed which target other steps in viral replication. One such target is the Rev trans-activator, which is essential for viral replication. The function of Rev is to induce-nuclear export of the partially spliced and unspliced viral messages, which encode the structural gene products and the RNA genome, for infectious HIV-1 particles. We propose to create a Rev-dependent, double reporter assay combined with Oncogene Science's unique cell based high-throughput screening technology, which is capable of evaluating over 123,000 compounds per year, to identify lead compounds from the NCI's natural product repository, which specifically inhibit the HIV-1 Rev trans- activator.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TRANSLOCATION ASSAY BY PCR AMPLIFICATION IN SITU
  • 批准号:
    3493086
  • 项目类别:
  • 资助金额:
    $4.86万
  • 财政年份:
    1992
  • 负责人:
    Anilkumar Dhundale
  • 依托单位:
YEAST MRNA 3' END FORMATION AS AN ANTIFUNGAL DRUG TARGET
  • 批准号:
    3489044
  • 项目类别:
  • 资助金额:
    $4.94万
  • 财政年份:
    1989
  • 负责人:
    Anilkumar Dhundale
  • 依托单位:
海外基金